CoChat

Do sulphonylureas still have a place in clinical practice?

The DOI matches its Crossref record; 70 of the 72 references it cites were found in a registry or an index.

Abstract

Sulphonylureas have been commercially available since the 1950s, but their use continues to be associated with controversy. Although adverse cardiovascular outcomes in some observational studies have raised concerns about sulphonylureas, findings from relatively recent, robust, and high-quality systematic reviews have indicated no increased risk of all-cause mortality associated with sulphonylureas compared with other active treatments. Results from large, multicentre, randomised controlled trials such as the UK Prospective Diabetes Study and ADVANCE have confirmed the microvascular benefits of sulphonylureas, a reduction in the incidence or worsening of nephropathy and retinopathy, and no increase in all-cause mortality, although whether these benefits were due to sulphonylurea therapy and not an overall glucose-lowering effect could not be confirmed. A comparison of sulphonylureas and pioglitazone in the TOSCA.IT trial also confirmed the efficacy and cardiovascular safety of sulphonylureas. Investigators of randomised controlled trials have reported an increased risk of hypoglycaemia and weight gain with sulphonylureas, but data from observational studies suggest that the incidence of severe hypoglycaemia is lower in people taking sulphonylurea than in people taking insulin, and weight gain with sulphonylureas has been relatively modest in large cohort studies. 80% of people with diabetes live in low-to-middle income countries, so the effectiveness, affordability, and safet…

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(18)30025-1

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 70 references

Research works printed but not linked: 1

  1. Janbon, 1942, Accidents hypoglycemiques graves par un sulfamidothiodiazol (le VK 57 ou 2254 RP), Montpellier Med, 441, 21

Cited by

See all 122

Metadata

Authors
Khunti, K., Chatterjee, S., Gerstein, H. C., Zoungas, S., & Davies, M. J.
Affiliations
  • University of Leicester (GB)
  • Population Health Research Institute (CA)
  • The George Institute for Global Health (AU)
Corresponding author
Khunti, Kamlesh
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2018-10
Volume
6
Issue
10
Pages
821-832
ISSN
2213-8587 (ISSN-L)
OpenAlex
W2789044349
Cited by
116
References
72
Citations by year
2026: 7 · 2025: 7 · 2024: 14 · 2023: 12 · 2022: 10 · 2021: 18 · 2020: 22 · 2019: 16 · 2018: 10
FWCI
2.54
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Sanofi
  • University of Leicester
  • Boehringer Ingelheim
  • Loughborough University
  • Janssen Pharmaceuticals
  • Novo Nordisk
  • Merck Sharp and Dohme
  • Collaboration for Leadership in Applied Health Research and Care - Greater Manchester
  • Merck
  • National Institute for Health and Care Research
  • Eli Lilly and Company
  • AstraZeneca
  • Amgen
  • University Hospitals of Leicester NHS Trust
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
sulfonylureas, type 2 diabetes, glucose-lowering therapy, cardiovascular safety, all-cause mortality, hypoglycemia, weight gain, kidney disease, retinopathy, pioglitazone, glimepiride, linagliptin, insulin comparison, low- and middle-income countries, glycemic control
MeSH terms
Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Risk Factors, Sulfonylurea Compounds, Randomized Controlled Trials as Topic, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Do sulphonylureas still have a place in clinical practice? https://app.cochat.ai/papers/10.1016/s2213-8587(18)30025-1
The paper
Khunti, K., Chatterjee, S., Gerstein, H. C., Zoungas, S., & Davies, M. J. (2018). Do sulphonylureas still have a place in clinical practice? The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(18)30025-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.